The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma : Episode 1
Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel
This video episode follows the journey of a 55-year-old female tech CEO with multiple myeloma, highlighting her treatments, relapse challenges, and transition to ide-cel, supported by her active lifestyle and strong support network.
- 55-year-old female, CEO of tech startup, diagnosed with multiple myeloma 5 years ago
- Initial treatment: 4 cycles DVRd, followed by ASCT and maintenance therapy
- Relapsed after 18 months and received KPd, but stopped after neurotoxicity and cardiac toxicity
- Otherwise healthy, active lifestyle, strong support system
- Receives ide-cel
Recent Videos
Related Content
